NKTR-255 clinical trials
Also written NKTR-255.
How each study uses NKTR-255 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the NKTR-255 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- NKTR-255
- 4
Studies by the year they started
5 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
Nektar Therapeutics (3) · Stanford University (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses NKTR-255 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)RecruitingPhase 2M.D. Anderson Cancer CenterNCT05632809Written as NKTR-255
- NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell LymphomaTerminatedPhase 2/3Nektar TherapeuticsNCT05664217Written as NKTR-255 at 1.5 µg/kg
- CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell MalignanciesActive, not recruitingPhase 1Stanford UniversityNCT03233854Written as NKTR-255
- Study of NKTR 255 in Combination With Cetuximab in Solid TumorsCompletedPhase 1/2Nektar TherapeuticsNCT04616196Written as NKTR-255
- NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin LymphomaCompletedPhase 1Nektar TherapeuticsNCT04136756Written as NKTR-255
Given beside what is tested · 1 — NKTR-255 is usual care or a partner of the new treatment
Codes
What other systems call NKTR-255 · ClinicalTrials.gg INT001776
- MeSH (NLM) C000720852NKTR-255One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720852 | NKTR-255 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.